TAK Stock Recent News

Takeda Pharmaceutical Co. Ltd. TAK, +0.43% 4502, +0.65% said Monday that it will acquire Hutchmed's HCM, +1.46% 13, +1.10% experimental cancer treatment outside mainland China, Hong Kong and Macau, with plans to develop and commercialize fruquintinib.

Shares in Hutchmed (China) Ltd jumped 6.5% after it announced a licensing deal with Takeda Pharmaceutical worth US$1.13bn. With an upfront payment of US$400mln plus milestones, the agreement allows the Japanese group to develop Hutchmed's cancer treatment, fruquintinib, outside China.

Entyvio is Takeda's key growth driver, and the management expects it to offset the effect of Vyvanse's patent expiration next year. The company aims to improve margins on its plasma-derived therapies (PDT) and is already seeing some signs in this regard.

OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Takeda ( TSE:4502/NYSE:TAK ) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda's latest research focuses on improving long-term outcomes for patients with hematologic diseases.

Strong top-line growth exhibited in FY22. Building regulatory and clinical momentum around its core offerings, with the bulk of the portfolio up double digits this year.

Is now the time to load up on these high-yielding investments?

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2022 Results Conference Call October 27, 2022 5:30 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andrew Plump - President, R&D Costa Saroukos - CFO Ramona Sequeira - President, Global Portfolio Division Teresa Bitetti - President, Global Oncology Business Unit Julie Kim - President, US Business Unit Giles Platford - President, Plasma-Derived Therapies Business Unit Masato Iwasaki - Representative Director, Japan General Affairs Conference Call Participants Hidemaru Yamaguchi - Citi Stacy Ku - Cowen Motoya Koutani - Nomura Securities Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Fumiyoshi Sakai - Credit Suisse Securities Akinori Ueda - Goldman Sachs Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Hiroaki Hashimoto - Nikkei BP Ayako Iwamuro Thank you very much for taking time out of your busy schedule to join us today for Takeda's Financial Results Webinar for the Second Qua

TAK vs. ZTS: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

These stocks both yield more than three times the S&P 500 average.